10-Q: NewAmsterdam Pharma Reports First Quarter 2025 Financial Results and Provides Business Update

NewAmsterdam Pharma reports its financial results for the first quarter of 2025, highlighting revenue from its Menarini license and progress in clinical development.

Summary

• NewAmsterdam Pharma Company N.V. reported a net loss of $39.5 million for the three months ended March 31, 2025, compared to a net loss of $93.8 million for the same period in 2024.
• Revenue increased to $3.0 million from $1.4 million year-over-year, driven by the Menarini license agreement.
• Research and development expenses increased slightly to $44.8 million from $42.4 million.
• Selling, general, and administrative expenses increased significantly to $27.2 million from $14.5 million.
• The company's cash and cash equivalents totaled $748.4 million as of March 31, 2025, compared to $771.7 million at the end of 2024.
• The reduction in cash is primarily due to ongoing operating expenditures, partially offset by development cost contributions from Menarini and cash received from interest and the exercise of options.
• The company has an accumulated loss of $598.1 million as of March 31, 2025.
• The company did not sell any Ordinary Shares pursuant to the Sales Agreement during the three months ended March 31, 2025.
• The company issued 1,743,136 Ordinary Shares in March 2025 related to the earnout milestone triggering event set forth in the Business Combination Agreement.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While revenue increased and the net loss decreased compared to the previous year, the company continues to operate at a loss and faces significant risks and competition. The substantial cash position provides some stability, but the increasing operating expenses are a concern.

Positives

• Revenue increased by 113% compared to the same period last year, driven by the Menarini license agreement.
• Net loss decreased significantly from $93.8 million to $39.5 million year-over-year.
• Interest income increased due to higher cash and marketable securities balances.
• The company has a substantial cash position of $748.4 million.

Negatives

• The company continues to incur net losses, with a $39.5 million loss for the quarter.
• Selling, general, and administrative expenses increased significantly, driven by personnel and marketing costs.
• The company has an accumulated loss of $598.1 million as of March 31, 2025.

Risks

• The company is dependent on the success of obicetrapib, and its clinical trials may not adequately demonstrate safety and efficacy.
• Regulatory approval processes are lengthy and unpredictable, and the company may not obtain regulatory approval for obicetrapib.
• Obicetrapib may produce undesirable side effects that could prevent approval or market acceptance.
• The company faces significant competition from competing therapies.
• The company relies on third-party contractors for manufacturing, and any disruptions could delay development or commercialization.
• The company's international operations are subject to various risks, including foreign exchange risk.
• The company may not be successful in obtaining all necessary intellectual property rights.
• Sales of a substantial number of securities could cause the price of Ordinary Shares and warrants to fall.
• The company no longer qualifies as an emerging growth company, resulting in increased disclosure requirements and expenses.

Future Outlook

The company expects to continue to incur significant losses for the foreseeable future as it continues clinical development of obicetrapib and pursues regulatory approval. The company may require additional capital to pursue clinical activities, complete clinical trials, and obtain regulatory approval for and commercialize obicetrapib.

Management Comments

• We seek to fill a significant unmet need for a safe, well tolerated and convenient low-density lipoprotein cholesterol (LDL-C) lowering therapy.
• We believe that CETP inhibition may also play a role in other indications by potentially mitigating the risk of developing diseases such as Alzheimers disease.
• We believe that obicetrapib has the potential to be a once-daily oral CETP inhibitor for lowering LDL-C, if approved.
• Our goal is to develop and commercialize an LDL-C lowering monotherapy and a fixed-dose combination therapy, which offers the advantage of a single, low dose, once-daily oral pill, and fulfills the significant unmet need for an effective and convenient LDL-C lowering therapy.

Industry Context

The report highlights the competitive landscape of the biopharmaceutical industry, particularly in LDL-C lowering therapies, with competition from PCSK9 inhibitors and oral therapeutics. The company aims to address the unmet needs of patients who do not achieve acceptable LDL-C levels with statin therapy alone, emphasizing the convenience and tolerability of obicetrapib.

Comparison to Industry Standards

• The document mentions competition from PCSK9 inhibitor injectables from Amgen Inc., Regeneron Pharmaceuticals, Inc. and Novartis International AG, which are established players in the LDL-C lowering market.
• It also acknowledges competition from oral therapeutics containing bempedoic acid from Esperion, indicating a shift towards more convenient oral administration.
• The document notes that Merck has decided to advance its oral PCSK9 inhibitor, MK-0616, into Phase 3 development and AstraZeneca has advanced its oral PCSK9 inhibitor, AZD0780, into Phase 2 development, which could pose additional competition for obicetrapib.
• The document references the REVEAL trial with the CETP inhibitor, anacetrapib, which showed major adverse cardiovascular events (MACE) benefit in trials of LDL-C lowering drugs.

Stakeholder Impact

• Shareholders: The company's financial performance and progress in clinical development will impact shareholder value.
• Employees: The company's growth and success will affect employment opportunities and job security.
• Patients: The development and approval of obicetrapib could provide a new treatment option for patients with cardiometabolic diseases.
• Suppliers and CROs: The company's operations will generate business for suppliers and CROs.

Next Steps

• Continue clinical development of obicetrapib.
• Pursue regulatory approval for obicetrapib in the United States, the EU, the United Kingdom, Japan and China.
• Commercialize obicetrapib in the United States, if approved.
• Collaborate with Menarini for commercialization in certain European areas.
• Consider additional partnerships for jurisdictions outside of the United States and the European Union.
• Evaluate potential acquisition or license of new product candidates.

Key Dates

Keywords

Obicetrapib, Cardiometabolic diseases, LDL-C lowering, Clinical trials, Menarini, Financial results, Revenue, Net loss, Research and development, Regulatory approval